The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cyclin-dependent kinases as therapeutic targets: Examination of palbociclib (PD 0332991) and flavopiridol in human tumor primary culture microspheroids.
Robert Alan Nagourney
Employment or Leadership Position - Rational Therapeutics
Stock Ownership - Rational Therapeutics
Eknath A. Deo
No relevant relationships to disclose
Nilesh L. Vora
No relevant relationships to disclose
Milan Rohit Sheth
No relevant relationships to disclose
Paula J Bernard
Employment or Leadership Position - Rational Therapeutics
Federico R Francisco
Employment or Leadership Position - Rational Therapeutics
Steven S Evans
Employment or Leadership Position - Rational Therapeutics